News | Prostate Cancer | January 18, 2017

PI-RADS Named Best Clinical Research Paper by European Urology

Prostate Imaging Reporting and Data System provides standardized reporting scheme

prostate cancer, PI-RADS, best clinical research paper, European Urology

January 18, 2017 — An article promoting standardized imaging efforts to improve diagnosis and treatment of prostate cancer has been selected as the best clinical research paper published in European Urology

“PI-RADS Prostate Imaging — Reporting and Data System: 2015, Version 2,” written by members of the MR Prostate Imaging Reporting and Data System (PI-RADS) Steering Committee, was published January 2016 in the official journal of the European Association of Urology (EAU). The article provides updated information for the acquisition and standardized interpretation and reporting of multiparametric magnetic resonance imaging (MRI) of the prostate to detect potentially life-threatening cancers.

“Since the publication of this paper last year, the newest version of PI-RADS has been welcomed with open arms and rapidly implemented by the prostate cancer medical community. The positive impact has been tremendous on both clinical care and research concerning the risk of clinically significant prostate cancer that may require biopsy and treatment,” said Jeffrey C. Weinreb, M.D., FACR, co-chair of the MR Prostate Imaging Reporting and Data System (PI-RADS) Steering Committee. Written for medical professionals, the online document along with the European Urology article represent an international scientific consensus, he added. Weinreb noted the steering committee was honored that its efforts received this international distinction. The award will be presented at the EAU annual meeting in March.

The American College of Radiology (ACR) formed a joint effort with AdMeTech Foundation and the European Society of Urogenital Radiology (ESUR) to expedite the transfer of high-quality MRI from laboratories to patients to address a major need in prostate cancer care — reducing unnecessary biopsies and treatment.

Members of the steering committee and authors of the journal article include Weinreb; Jelle O. Barentsz, M.D., Ph.D. (co-chair); Peter L. Choyke, M.D., FACR; François Cornud, M.D.; Masoom A. Haider, M.D.; Katarzyna J. Macura, M.D., Ph.D., FACR; Daniel Margolis, M.D.; Mitchell D. Schnall, M.D., Ph.D., FACR; Clare M. Tempany, M.D.; Harriet C. Thoeny, M.D.; and Sadhna Verma, M.D.

For more information: www.europeanurology.com

References

Weinreb, J.C., Barentsz, J.O., Choyke, P.L., Cornud, F., et al. "PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2," European Urology. Published Jan. 1, 2016. DOI: 10.1016/j.eururo.2015.08.052

Related Content

Researchers at Karolinska Institutet in Sweden and Tampere University in Finland have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer

From left: Peter Ström, Martin Eklund, Kimmo Kartasalo, Henrik Olsson och Lars Egevad, researchers at Karolinska Institutet in Sweden. Photo courtesy of Stefan Zimmerman

News | Prostate Cancer | January 20, 2020
January 20, 2020 — Researchers at Karolinska Institutet in Sweden and...
Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society

News | Radiation Oncology | January 13, 2020
January 13, 2020 — The cancer death rate declined
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewha
prostate cancer UCL study
News | Prostate Cancer | January 03, 2020
January 3, 2020 — Nearly one in six deaths from...
Effective Jan. 1, 2020, new regulations under the Centers for Medicare & Medicaid Services (CMS) Protecting Access to Medicare Act (PAMA) will require physicians to consult a CMS-approved clinical decision support mechanism before ordering advanced imaging exams for fee-for-service Medicare patients
News | Clinical Decision Support | December 26, 2019
December 26, 2019 — Effective Jan.
Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter

Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter. Standard MRI or CT are not able to detect lymph node metastases smaller than 7 – 8 mm. Since most of the oncologic patients are dying due to metastases, a precise diagnostic is of utmost importance. The detection of small metastases, combined with the very clear and contrast rich MRI image of Ferrotran, enables an earlier and more precise treatment. Therefore, Ferrotran gives the patient a much higher chance of recovery.

News | Prostate Cancer | December 24, 2019
December 24, 2019 — SPL Medical announced today that the first patient has been successfully diagnosed with suspected
Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital.

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital. Photo courtesy of Thorsten Mohr/Saarland University

News | Prostate Cancer | November 28, 2019
November 28, 2019 — Reports of new cancer treatments
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...